AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15745869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 65
Study 11737692 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin (20 mg/kg/day for 6 weeks)
Number of subjects: 200
Study 11737692 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (> 40 kg: 250 mg; 20-40 kg: 125 mg; < 20 kg: 62.5 mg for 2-3 weeks)
Number of subjects: 200
Study 11737692 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (5 mg/kg/day for 2-3 weeks)
Number of subjects: 200
Study 11737692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg/day for 2-3 weeks)
Number of subjects: 200
Study 9415509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (400 mg)
Number of subjects: 14
Study 9415509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8236387 — intervention group
Group type: EXPERIMENTAL
Intervention: Community involvement in Aedes aegypti control programme
Number of subjects: 0
Study 8236387 — intervention group
Group type: COMPARATOR
Intervention: Untreated neighborhoods
Number of subjects: 0
Study 3631772 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline inhaled with a tube spacer
Number of subjects: 18
Study 3631772 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline inhaled without a tube spacer (conventional inhaler)
Number of subjects: 18
Study 31076466 — intervention group
Group type: EXPERIMENTAL
Intervention: Online acceptance and commitment therapy (ACT) intervention, 8 sessions over 8 weeks
Number of subjects: 192
Study 31076466 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 192
Study 27618363 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 6975
Study 27618363 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6975
Study 25753087 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Fentanyl patches
Number of subjects: 196
Study 25753087 — intervention group
Group type: COMPARATOR
Intervention: Patient Controlled Analgesia (PCA)
Number of subjects: 196
Study 24089671 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM200
Number of subjects: 9
Study 24089671 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM140 + TMI 8 Gy
Number of subjects: 9
Study 21297553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS) (2880 mg/day for days 0-14, 2160 mg/day for days 15-42, followed by 1440 mg/day)
Number of subjects: 128
Study 21297553 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (SD) regimen of enteric-coated mycophenolate sodium (EC-MPS) (1440 mg/day)
Number of subjects: 128
Study 21297553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 128
Study 21297553 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (SD) regimen of enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 128
Study 21297553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ID and SD regimens
Number of subjects: 128
Study 19805674 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 30 mg IV three times weekly for up to 3 months and pentostatin 4 mg/m2 IV weekly for 4 weeks followed by alternate weekly administration for up to 6 months
Number of subjects: 24
Study 19805674 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab and pentostatin
Number of subjects: 24
Study 19805674 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics including antiviral, antifungal, and antibacterial agents
Number of subjects: 24
Study 16939066 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS, myfortic) 720 mg b.i.d. with cyclosporine microemulsion and corticosteroids
Number of subjects: 297
Study 16939066 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS, myfortic)
Number of subjects: 297
Study 16939066 — intervention group
Group type: COMPARATOR
Intervention: Conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 297
Study 15246599 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study 15246599 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide vaccine
Number of subjects: 0
Study 15246599 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 11374602 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 1 x 10(6) KIU/h, 1 x 10(6) KIU before reperfusion; n = 24)
Number of subjects: 67
Study 11374602 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 0.5 x 10(6) KIU/h; n = 21)
Number of subjects: 67
Study 11374602 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 67
Study 11823998 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 930
Study 11823998 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 930
Study 1414239 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam (800 mg tablet), twice daily for 12 weeks
Number of subjects: 65
Study 1414239 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 12 weeks
Number of subjects: 65
Study 3919076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 14
Study 3919076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30316960 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity home-based respiratory muscle training (40 minutes, 7 days/week for 8 weeks)
Number of subjects: 38
Study 30316960 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham intervention of similar dose)
Number of subjects: 38
Study 29386172 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Collaborative Depression Care (RCDC), N=65, 3-month treatment with continuous remote supervision by psychiatrists through shared electronic health records (SEHR) and phone monitoring.
Number of subjects: 143
Study 29386172 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC), N=78, provided by clinicians following clinical guidelines.
Number of subjects: 143
Study 29386172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RCDC and EUC).
Number of subjects: 143
Study 28239635 — intervention group
Group type: EXPERIMENTAL
Intervention: Work, Family and Health Study intervention aimed at reducing work-family conflict through interactive sessions and training in family-supportive supervision.
Number of subjects: 1706
Study 28239635 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1706
Study 28239635 — intervention group
Group type: EXPERIMENTAL
Intervention: Work, Family and Health Study intervention
Number of subjects: 1706
Study 24210149 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable braided sutures (Vycril; Ethicon)
Number of subjects: 200
Study 24210149 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable monofilament sutures (Prolene; Ethicon)
Number of subjects: 200
Study 22464674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bacterial lysate (heat‐killed Escherichia coli and Enterococcus faecalis) from week 5 until the end of month 7
Number of subjects: 606
Study 22464674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 22464674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bacterial lysate
Number of subjects: 606
Study 20383345 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 14 days
Number of subjects: 211
Study 20383345 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg orally twice daily for 21 days
Number of subjects: 211
Study 18977834 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal radius vascularised bone graft
Number of subjects: 80
Study 18977834 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest non‐vascularised bone graft
Number of subjects: 80
Study 15750458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (2 mg/kg)
Number of subjects: 179
Study 12427146 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 1200 mg one hour before angiography and a second dose 3 hours after; IV hydration
Number of subjects: 79
Study 12427146 — intervention group
Group type: COMPARATOR
Intervention: Placebo; IV hydration
Number of subjects: 79
Study 12427146 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in patients with diabetes mellitus
Number of subjects: 79
Study 12427146 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with diabetes mellitus
Number of subjects: 79
Study 10520903 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 43
Study 10520903 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein graft (SVG)
Number of subjects: 43
Study 8719696 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (intervention for acute demyelinating optic neuritis)
Number of subjects: 488
Study 1399301 — intervention group
Group type: EXPERIMENTAL
Intervention: wide spectrum intravenous antibiotics and suction and debridement
Number of subjects: 48
Study 3160322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin sodium (20 mg/kg)
Number of subjects: 40
Study 3160322 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin sodium (30 mg/kg)
Number of subjects: 40
Study 29549483 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgluteal group (n=80; treated in the supine position using a transgluteal approach)
Number of subjects: 160
Study 29549483 — intervention group
Group type: COMPARATOR
Intervention: Prone group (n=80; treated in the conventional prone position)
Number of subjects: 160
Study 27754427 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03
Number of subjects: 15
Study 27754427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone deficiency syndrome (TDS) in MS patients
Number of subjects: 77
Study 23488280 — intervention group
Group type: COMPARATOR
Intervention: Testosterone deficiency syndrome (TDS) in obese patients without MS
Number of subjects: 77
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: MS(+) group
Number of subjects: 77
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: MS(+) TDS(+) group
Number of subjects: 77
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TT and body weight in MS(+) group
Number of subjects: 77
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SHBG and waist circumference in MS(+) group
Number of subjects: 77
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SHBG and body weight in MS(+) group
Number of subjects: 77
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SHBG and age in MS(+) group
Number of subjects: 77
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting lipid levels, fasting blood glucose, CRP, Fb, BP
Number of subjects: 77
Study 23488280 — intervention group
Group type: EXPERIMENTAL
Intervention: TT, fT, SHBG and IIEF-5, AMS score
Number of subjects: 77
Study 20393809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40
Study 20393809 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 40
Study 19951404 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, multidisciplinary care involving a dermatologist, care manager, specialized nurse, and clinical occupational physician.
Number of subjects: 0
Study 19951404 — intervention group
Group type: COMPARATOR
Intervention: Usual care by a dermatologist.
Number of subjects: 0
Study 18020888 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy
Number of subjects: 500
Study 18020888 — intervention group
Group type: COMPARATOR
Intervention: No hormonal replacement therapy
Number of subjects: 500
Study 18020888 — intervention group
Group type: EXPERIMENTAL
Intervention: Female population aged 40-44 years
Number of subjects: 500
Study 15516696 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg daily)
Number of subjects: 250
Study 15516696 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg daily)
Number of subjects: 250
Study 15516696 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan and Enalapril
Number of subjects: 250
Study 11212625 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions adhering to the Morton-Massaro law (MML)
Number of subjects: 0
Study 11212625 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural stimuli analyses
Number of subjects: 0
Study 11212625 — intervention group
Group type: EXPERIMENTAL
Intervention: Feed-forward and interactive models
Number of subjects: 0
Study 9516894 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 100 mg once daily
Number of subjects: 19
Study 9516894 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 50 mg twice daily
Number of subjects: 19
Study 9516894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8458257 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine (200 mg/day per os) for one month
Number of subjects: 24
Study 8458257 — intervention group
Group type: COMPARATOR
Intervention: Placebo for one month
Number of subjects: 24
Study 3802303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg/die/p.o.
Number of subjects: 38
Study 3802303 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg/die/p.o.
Number of subjects: 38
Study 29948994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 150
Study 29948994 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 150
Study 26883644 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS consultation intervention
Number of subjects: 79
Study 26883644 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger parent-teacher alliance
Number of subjects: 79
Study 25052238 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg 3 times daily for 5 days
Number of subjects: 30
Study 25052238 — intervention group
Group type: COMPARATOR
Intervention: Placebo 10 mg 3 times daily for 5 days
Number of subjects: 30
Study 21926427 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 IM/PM genotypic category
Number of subjects: 196
Study 21926427 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*17 allele (UM phenotype)
Number of subjects: 196
Study 21926427 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 PM phenotype
Number of subjects: 196
Study 20395869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg every day for 4 days
Number of subjects: 24
Study 20395869 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice a day for 4 days
Number of subjects: 24
Study 20395869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg every day + Raltegravir 400 mg twice a day for 4 days
Number of subjects: 24
Study 18315579 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 1 g o.d. for 3 months
Number of subjects: 41
Study 18315579 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 41
Study 18315579 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 1 g o.d. for 1 month
Number of subjects: 41
Study 18315579 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 41
Study 15737906 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral dose <150% minimum peripheral dose (mPD)
Number of subjects: 108
Study 15737906 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral dose 150% minimum peripheral dose (mPD)
Number of subjects: 108
Study 15737906 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotope used in brachytherapy
Number of subjects: 108
Study 15737906 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplant International Prostate Symptom Score (I‐PSS)
Number of subjects: 108
Study 15737906 — intervention group
Group type: EXPERIMENTAL
Intervention: D(90)
Number of subjects: 108
Study 12463428 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 69
Study 12463428 — intervention group
Group type: COMPARATOR
Intervention: 0.25% racemic bupivacaine
Number of subjects: 69
Study 10327193 — intervention group
Group type: EXPERIMENTAL
Intervention: MDV2 double-immunostaining method
Number of subjects: 0
Study 7549303 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo) 150 U/kg three times per week given sc
Number of subjects: 24
Study 7549303 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 2027118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug
Number of subjects: 0
Study 2027118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7004470 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.15 mg per kg body weight i.v.
Number of subjects: 0
Study 7004470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propranolol)
Number of subjects: 0
Study 31454045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem transplant with thiotepa/cyclophosphamide followed by dose-reduced carboplatin/etoposide/melphalan (n = 176)
Number of subjects: 355
Study 31454045 — intervention group
Group type: COMPARATOR
Intervention: Single transplant with carboplatin/etoposide/melphalan (n = 179)
Number of subjects: 355
Study 28303328 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoyl-KVK-L-ascorbic acid cream
Number of subjects: 0
Study 28303328 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoyl-KVK-L-ascorbic acid (20 μg/mL)
Number of subjects: 0
Study 28303328 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 25818278 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in a contextually enhanced environment for 8 weeks
Number of subjects: 0
Study 25818278 — intervention group
Group type: COMPARATOR
Intervention: Exercise in a standard environment for 8 weeks
Number of subjects: 0
Study 25818278 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study 23873905 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted (LA) group
Number of subjects: 82
Study 23873905 — intervention group
Group type: COMPARATOR
Intervention: Free-hand group
Number of subjects: 82
Study 21537051 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vitamin E (800 U), soy (40 g), and selenium (200 μg)
Number of subjects: 303
Study 21537051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 19610264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fined wines containing egg albumin, lysozyme, milk casein, fish gelatin, or isinglass
Number of subjects: 14
Study 19610264 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfined wines
Number of subjects: 14
Study 19610264 — intervention group
Group type: COMPARATOR
Intervention: Fined and unfined wines
Number of subjects: 14
Study 17578197 — intervention group
Group type: EXPERIMENTAL
Intervention: Setegis (terazosin)
Number of subjects: 0
Study 17578197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with alpha-adrenoblockers
Number of subjects: 0
Study 17578197 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with antibacterial drugs
Number of subjects: 0
Study 15152897 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release melatonin 2 mg
Number of subjects: 30
Study 15152897 — intervention group
Group type: EXPERIMENTAL
Intervention: zopiclone 5 mg
Number of subjects: 30
Study 15152897 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 11146789 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 120
Study 11146789 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg
Number of subjects: 120
Study 11146789 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 4 mg
Number of subjects: 120
Study 11146789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9520629 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training and heat acclimation (8 weeks training followed by 6 days acclimation)
Number of subjects: 24
Study 9520629 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat acclimation (6 or 12 days)
Number of subjects: 24
Study 9520629 — intervention group
Group type: COMPARATOR
Intervention: Endurance training and heat acclimation
Number of subjects: 24
Study 8005275 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (P) 50 mg/d
Number of subjects: 100
Study 8005275 — intervention group
Group type: COMPARATOR
Intervention: Progesterone (P) 50 mg/d + Estrogen (E2) valerate 2 mg/d
Number of subjects: 100
Study 2510272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms b.d.
Number of subjects: 257
Study 2510272 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg b.d.
Number of subjects: 257
Study 790546 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day of ketoprofen
Number of subjects: 50
Study 790546 — intervention group
Group type: COMPARATOR
Intervention: 600 mg/day of phenylbutazone
Number of subjects: 50
Study 790546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (ketoprofen and phenylbutazone)
Number of subjects: 50
Study 790546 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoprofen
Number of subjects: 50
Study 790546 — intervention group
Group type: COMPARATOR
Intervention: phenylbutazone
Number of subjects: 50
Study 31491602 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG metrics analysis in ACS patients
Number of subjects: 4516
Study 31491602 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach and bivalirudin treatment
Number of subjects: 4516